Newland Pharmaceutical Co., Ltd. (SHE:301277)
China · Delayed Price · Currency is CNY 10.47
+0.15 (1.45%)
At close: Sep 30, 2026
Newland Pharmaceutical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 4,105 | 4,623 | 3,873 | 4,163 | 3,850 | - | |
Market Cap Growth | -17.62% | 19.35% | -6.96% | 8.12% | - | - |
Enterprise Value | 3,490 | 3,913 | 3,072 | 3,378 | 3,952 | - |
Last Close Price | 10.47 | 11.59 | 9.48 | 10.01 | 9.12 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 39.38 | 38.13 | 22.31 | 26.19 | 29.10 | - |
PS Ratio | 5.78 | 6.88 | 5.33 | 6.39 | 6.14 | - |
PB Ratio | 2.68 | 2.98 | 2.51 | 2.87 | 2.83 | - |
P/TBV Ratio | 2.76 | 3.08 | 2.57 | 2.95 | 2.92 | - |
P/FCF Ratio | 99.83 | 297.23 | 242.50 | 25.55 | 452.81 | - |
P/OCF Ratio | 45.26 | 39.53 | 30.56 | 16.04 | 46.47 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 4.91 | 5.82 | 4.23 | 5.19 | 6.30 | - |
EV/EBITDA Ratio | 21.48 | 22.74 | 14.20 | 17.72 | 23.61 | - |
EV/EBIT Ratio | 34.98 | 32.75 | 16.98 | 20.87 | 27.20 | - |
EV/FCF Ratio | 84.87 | 251.61 | 192.33 | 20.73 | 464.84 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.31 |
Debt / EBITDA Ratio | 0.03 | 0.03 | 0.01 | 0.01 | 0.03 | 0.80 |
Debt / FCF Ratio | 0.10 | 0.37 | 0.19 | 0.02 | 0.67 | 5.34 |
Net Debt / Equity Ratio | -0.40 | -0.46 | -0.52 | -0.59 | -0.55 | 0.21 |
Net Debt / EBITDA Ratio | -3.84 | -4.14 | -3.72 | -4.49 | -4.46 | 0.53 |
Net Debt / FCF Ratio | -14.94 | -45.84 | -50.33 | -5.26 | -87.83 | 3.53 |
Asset Turnover | 0.40 | 0.37 | 0.42 | 0.41 | 0.57 | 0.86 |
Inventory Turnover | 6.51 | 7.62 | 11.50 | 9.30 | 6.12 | 4.81 |
Quick Ratio | 5.93 | 5.81 | 5.26 | 7.89 | 7.14 | 1.42 |
Current Ratio | 6.52 | 6.26 | 5.51 | 8.29 | 7.61 | 1.82 |
Return on Equity (ROE) | 6.72% | 7.76% | 11.56% | 11.19% | 14.92% | 31.91% |
Return on Assets (ROA) | 3.54% | 4.16% | 6.61% | 6.44% | 8.25% | 14.32% |
Return on Invested Capital (ROIC) | 9.56% | 13.56% | 23.82% | 23.31% | 24.30% | 27.06% |
Return on Capital Employed (ROCE) | 6.30% | 7.40% | 11.30% | 11.00% | 10.50% | 30.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 2.53% | 2.62% | 4.48% | 3.82% | 3.44% | - |
FCF Yield | 1.00% | 0.34% | 0.41% | 3.91% | 0.22% | - |
Dividend Yield | 1.91% | 1.73% | 4.22% | 2.04% | 1.86% | - |
Payout Ratio | 75.41% | 92.39% | 46.08% | 41.94% | 5.12% | 31.92% |
Buyback Yield / Dilution | 0.13% | 0.88% | -1.05% | -29.52% | -2.59% | -0.64% |
Total Shareholder Return | 2.04% | 2.61% | 3.17% | -27.48% | -0.72% | -0.64% |